Research progress and prospect of immunotherapy in the treatment of melanoma
10.12092/j.issn.1009-2501.2021.09.012
- Author:
Wei LI
1
;
Jiali HU
1
;
Yijing HE
1
;
Wei LI
2
;
Jiali HU
2
;
Yijing HE
2
;
Kai WANG
3
Author Information
1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University
2. Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics
3. Department of Pharmacy, Hunan Provincial People's Hospital
- Publication Type:Journal Article
- Keywords:
Immunotherapy;
Limitation;
Melanoma
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(9):1053-1064
- CountryChina
- Language:Chinese
-
Abstract:
Cutaneous melanoma is an aggressive and potentially fatal skin cancer which is prone to distant metastasis and spread. Before the advent of targeted therapy and immunotherapy, the prognosis of patients with advanced melanoma is extremely poor, with a 5-year survival rate less than 10%. Compared with traditional treatment, immunotherapy can prolong the progression-free survival and overall survival of patients with advanced melanoma and improve patients' life quality. Although immune-related adverse reactions occur during clinical treatment, most of them could be controlled by giving appropriate immunomodulators. As immunotherapy has received certain attention in clinical, its limitations have also been discovered. Patients have been found to resist or insensitive to immunotherapy, suggesting that the combination therapy may bring greater benefits to clinical treatment. This paper summarized the current the progress and limitations of immunotherapy in clinic for cutaneous melanoma.
